Assessment of reported adverse events after substitution between TNF alfa inhibitors biosimilars in the WHO pharmacovigilance database

被引：0

作者：

Orhon, P. ^{[1
]}

Robert, M. ^{[1
]}

Bernardeau, C. ^{[1
]}

Fusaroli, M. ^{[2
]}

Roustit, M. ^{[3
]}

Cracowski, J. L. ^{[1
]}

Khouri, C. ^{[1
]}

机构：

[1] Grenoble Alpes Univ Hosp, Pharmacovigilance Unit, Grenoble, France

[2] Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy

[3] Grenoble Alpes Univ Hosp, Clin Pharmacol Dept, Grenoble, France

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PS-115

引用

页码：160 / 160

页数：1

共 50 条

[1] Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database [J].

Pauline, Orhon ;

Robert, Marion ;

Bernardeau, Claire ;

Hlavaty, Alex ;

Fusaroli, Michele ;

Roustit, Matthieu ;

Cracowski, Jean-Luc ;

Khouri, Charles .

BIODRUGS, 2023, 37 (05) :699-707

[2] Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database [J].

Orhon Pauline ;

Marion Robert ;

Claire Bernardeau ;

Alex Hlavaty ;

Michele Fusaroli ;

Matthieu Roustit ;

Jean-Luc Cracowski ;

Charles Khouri .

BioDrugs, 2023, 37 :699-707

[3] Analysis of Hydroxychloroquine Adverse Events Reported in the WHO Pharmacovigilance Database [J].

Ahmed, Nehad J. ;

Alshehri, Ahmed M. ;

Almalki, Ziyad S. ;

Alahmari, Abdullah K. .

LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (01) :25-30

[4] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database [J].

Hoisnard, Lea ;

Maury, Sebastien ;

Mahevas, Matthieu ;

El Karoui, Khalil ;

Roy, Lydia ;

Cohen, Jose L. ;

Amiot, Aurelien ;

Claudepierre, Pascal ;

Grimbert, Philippe ;

Sbidian, Emilie .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) :AB137-AB137

[5] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database [J].

Hoisnard, Lea ;

Lebrun-Vignes, Benedicte ;

Maury, Sebastien ;

Mahevas, Matthieu ;

El Karoui, Khalil ;

Roy, Lydia ;

Zarour, Anissa ;

Michel, Marc ;

Cohen, Jose L. ;

Amiot, Aurelien ;

Claudepierre, Pascal ;

Wolkenstein, Pierre ;

Grimbert, Philippe ;

Sbidian, Emilie .

SCIENTIFIC REPORTS, 2022, 12 (01)

[6] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database [J].

Hoisnard, L. ;

Lebrun-Vignes, B. ;

Maury, S. ;

Mahevas, M. ;

El Karoui, K. ;

Roy, L. ;

Zarour, A. ;

Michel, M. ;

Cohen, J. L. ;

Amiot, A. ;

Claudepierre, P. ;

Wolkenstein, P. ;

Grimbert, P. ;

Sbidian, E. .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 :165-165

[7] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database [J].

Léa Hoisnard ;

Bénédicte Lebrun-Vignes ;

Sébastien Maury ;

Matthieu Mahevas ;

Khalil El Karoui ;

Lydia Roy ;

Anissa Zarour ;

Marc Michel ;

José L. Cohen ;

Aurélien Amiot ;

Pascal Claudepierre ;

Pierre Wolkenstein ;

Philippe Grimbert ;

Emilie Sbidian .

Scientific Reports, 12

[8] Evaluation of adverse events related to musculoskeletal system reported for COVID-19 vaccines in VigiBase: A WHO pharmacovigilance database [J].

Kaur, Rimple Jeet ;

Charan, Jaykaran .

BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 :1176-1177

[9] Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database [J].

Cutroneo, P. M. ;

Arzenton, E. ;

Furci, F. ;

Bulzomi, M. ;

Caminati, M. ;

Senna, G. ;

Moretti, U. ;

Trifiro, G. .

DRUG SAFETY, 2022, 45 (10) :1160-1161

[10] A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database [J].

Zhang, Ya-Jun ;

Duan, Dan-Dan ;

Tian, Qian-Yu ;

Wang, Cai-E. ;

Wei, Shu-Xun .

FRONTIERS IN PHARMACOLOGY, 2024, 15

← 1 2 3 4 5 →